Cardiff Oncology opened lower at $0.75, compared with its previous close of $0.77. In the last trading session, the stock traded between $0.72 and $0.77. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Cardiff Oncology is now worth
$ 12.96
Resulting in a loss of
$ 87.04 (87.04%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 5 Analysts
Buy
40%
Hold
60%
Sell
0%
Markets Today
Today's Change
$-0.03 (-4.48%)
Day High
$0.77
Day Low
$0.72
Day Open
$0.75
Prev Close
$0.77
Volume
2,92,114
1W Return
-15.59%
1M Return
-30.05%
3M Return
-30.05%
6M Return
-55.15%
1Y Return
-68.08%
Fundamentals
Market Cap ($ Mn)
57
PE Ratio
-
PB Ratio
2.42
PEG Ratio
-
ROE
-74.77%
ROCE
-79.24%
EPS (TTM)
$-0.13
Investment Returns
1 Week
-15.59%
1 Month
-30.05%
3 Months
-30.05%
6 Months
-55.15%
9 Months
-54.31%
Financials
Quarterly
All values in $ Mn
0.1
Mar 25
0.1
Jun 25
0.1
Sep 25
0.2
Dec 25
0.0
Mar 26
0.1
Jun 26
Updates
12Nov
Cardiff Oncology Q3 Results: Loss narrows to $(0.12), revenue up 42.5%
Cardiff Oncology reported a Q3 loss of $(0.12) per share, beating the $(0.15) estimate by 20%. Quarterly revenue reached $171.000 thousand, exceeding the $67.857 thousand estimate by 152%. Loss per share narrowed 29.41% from $(0.17) in the same period last year. Revenue grew 42.50% YoY from $120.000 thousand.
Today
22Oct
Cardiff Oncology secures FDA Orphan Drug Designation for onvansertib
FDA granted Orphan Drug Designation to onvansertib for chronic myelomonocytic leukemia. 40-50% of myeloproliferative CMML patients have RAS-pathway mutations linked to aggressive disease. Phase 1 data showed preliminary efficacy in approximately 40% of myeloproliferative CMML patients. One patient achieved optimal marrow response, reducing bone marrow blasts from 8% to 2%. Designation provides tax credits, fee exemptions, and up to seven years of market exclusivity.
22 days ago
12Aug
Cardiff Oncology Q2 EPS beats; advances onvansertib to Phase 3
Cardiff Oncology delivered better-than-expected Q2 financials, beating EPS estimates by 12.5% and sales estimates by 47%, driven by cost reductions in R&D. Clinically, the company secured FDA alignment for a Phase 3 trial of onvansertib in colorectal cancer, supported by robust Phase 2 response rates. Despite a YoY revenue decline and ongoing litigation with licensor NMS, the company maintains a cash runway into Q3 2027, bolstered by a recent $10 million direct offering.
